title: Photodynamic therapy in the treatment of persistent central serous chorioretinopathy: a two-year follow-up.
abstract: BACKGROUND
  The aim of this study was to assess during a follow-up period of two years the efficacy and safety of photodynamic therapy (PDT) in central serous chorioretinopathy (CSC) showing no spontaneous resolution four months after the onset of the symptoms.
  
  
  METHODS
  We present a prospective interventional non-comparative case series. The diagnosis of CSC was confirmed by fluorescein angiography (FA), and optical coherence tomography (OCT) in 46 eyes of 42 consecutive patients. PDT was performed according to the protocol used for treating choroidal neovascularization in age-related macular degeneration. The primary end point was to assess the anatomic re-attachment of the retina. The secondary end point was to record the visual function. A paired t-test and a linear regression and correlation test were used for the statistics.
  
  
  RESULTS
  The leakage in FA and the detachment of the neurosensory retina in OCT were no longer present in 42 eyes six weeks after PDT and in the remaining four eyes three months after PDT. At the end of the follow-up, the best-corrected visual acuity measured with an ETDRS chart improved in 36 eyes, and remained stable in 10 eyes (mean improvement, 10.2 letters; p < 0.001). Two cases of recurrence were diagnosed. No treatment-related complications were noticed.
  
  
  CONCLUSIONS
  PDT could be an effective and durable option for treating patients with persistent CSC.
authors.affiliation: Department of Ophthalmology, Cantonal Hospital St. Gallen, Switzerland. christophe.valmaggia@kssg.ch
authors.forename: C
authors.initials: C
authors.lastname: Valmaggia
authors.forename: I
authors.initials: I
authors.lastname: Haueter
authors.forename: H
authors.initials: H
authors.lastname: Niederberger
mesh_terms: D056833:Central Serous Chorioretinopathy / Q000150:complications / Q000188:drug therapy* / Q000473:pathology*; D002908:Chronic Disease; D005500:Follow-Up Studies; D006801:Humans; D009883:Ophthalmic Solutions / Q000627:therapeutic use*; D010778:Photochemotherapy / Q000379:methods*; D017319:Photosensitizing Agents / Q000627:therapeutic use*; D016896:Treatment Outcome; D014786:Vision Disorders / Q000175:diagnosis / Q000209:etiology* / Q000517:prevention & control*
chemical_list: D009883:Ophthalmic Solutions; D017319:Photosensitizing Agents